EnGeneIC is a clinical stage biopharmaceutical company focused on developing its proprietary EDV™ nanocell platform for the targeted delivery of chemotherapeutics and functional nucleic acids in cancer. The EDV™ is a first-in-class Cyto-Immunotherapy platform that enables current cancer treatments to be more potent and far less toxic, while also stimulating a potent anti-tumor immune response.